EP1429747A4 - Core formulation comprising pioglitazone hydrochloride and a biguanide - Google Patents

Core formulation comprising pioglitazone hydrochloride and a biguanide

Info

Publication number
EP1429747A4
EP1429747A4 EP01952548A EP01952548A EP1429747A4 EP 1429747 A4 EP1429747 A4 EP 1429747A4 EP 01952548 A EP01952548 A EP 01952548A EP 01952548 A EP01952548 A EP 01952548A EP 1429747 A4 EP1429747 A4 EP 1429747A4
Authority
EP
European Patent Office
Prior art keywords
biguanide
pioglitazone hydrochloride
core formulation
formulation
core
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01952548A
Other languages
German (de)
French (fr)
Other versions
EP1429747A1 (en
Inventor
Akwete L Adjei
Yaping Zhu
Anthony J Cutie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kos Life Sciences Inc
Original Assignee
Kos Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kos Life Sciences Inc filed Critical Kos Life Sciences Inc
Publication of EP1429747A1 publication Critical patent/EP1429747A1/en
Publication of EP1429747A4 publication Critical patent/EP1429747A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
EP01952548A 2001-07-10 2001-07-10 Core formulation comprising pioglitazone hydrochloride and a biguanide Withdrawn EP1429747A4 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2001/021615 WO2003005995A1 (en) 2001-07-10 2001-07-10 Core formulation comprising pioglitazone hydrochloride and a biguanide

Publications (2)

Publication Number Publication Date
EP1429747A1 EP1429747A1 (en) 2004-06-23
EP1429747A4 true EP1429747A4 (en) 2005-01-05

Family

ID=21742689

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01952548A Withdrawn EP1429747A4 (en) 2001-07-10 2001-07-10 Core formulation comprising pioglitazone hydrochloride and a biguanide

Country Status (6)

Country Link
EP (1) EP1429747A4 (en)
JP (1) JP2004536843A (en)
AU (1) AU2001273289B2 (en)
CA (1) CA2453775A1 (en)
MX (1) MXPA04000180A (en)
WO (1) WO2003005995A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1429732A4 (en) * 2001-07-10 2005-01-26 Kos Life Sciences Inc A core formulation
AU2003281181A1 (en) * 2002-07-11 2004-02-02 Takeda Pharmaceutical Company Limited Process for producing coated preparation
KR101114808B1 (en) 2003-01-29 2012-02-15 다케다 야쿠힌 고교 가부시키가이샤 Process for producing coated preparation
EP1656120B1 (en) * 2003-07-19 2012-11-28 Warren Ward Compositions comprising components coated with a liquid impermeable but gas permeable layer, use thereof for treating cutaneous and other exocrine gland diseases
GB0316940D0 (en) * 2003-07-19 2003-08-27 Ward Warren Treatment of skin and other medical conditions
US20070078170A1 (en) * 2003-08-28 2007-04-05 Khanduri Chandra H Process for the preparation of pioglitazone
WO2006076191A2 (en) * 2005-01-10 2006-07-20 Elc Management Llc Discontinuous surface coating for particles
MXPA05014092A (en) * 2005-12-20 2007-06-20 Leopoldo De Jesus Espinosa Abdala Pharmaceutical compositions containing derivative substances of thiazolidinediones combined with a biguanide for use in type 2 diabetes mellitus.

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997041842A1 (en) * 1996-05-09 1997-11-13 The Trustees Of The University Of Pennsylvania Hollow bone mineral-like calcium phosphate particles
WO1999003477A1 (en) * 1997-07-18 1999-01-28 Smithkline Beecham P.L.C. Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
WO2000044681A2 (en) * 1999-02-01 2000-08-03 The Curators Of The University Of Missouri Method for preparing porous shells or gels from glass particles
WO2001082875A2 (en) * 2000-05-01 2001-11-08 Aeropharm Technology, Inc. A core formulation
WO2003005991A1 (en) * 2001-07-10 2003-01-23 Aeropharm Technology Incorporated A core formulation
WO2003005993A1 (en) * 2000-05-01 2003-01-23 Aeropharm Technology Incorporated Core formulation comprising troglitazone and a biguanide

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997041842A1 (en) * 1996-05-09 1997-11-13 The Trustees Of The University Of Pennsylvania Hollow bone mineral-like calcium phosphate particles
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
WO1999003477A1 (en) * 1997-07-18 1999-01-28 Smithkline Beecham P.L.C. Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide
WO2000044681A2 (en) * 1999-02-01 2000-08-03 The Curators Of The University Of Missouri Method for preparing porous shells or gels from glass particles
WO2001082875A2 (en) * 2000-05-01 2001-11-08 Aeropharm Technology, Inc. A core formulation
WO2003005993A1 (en) * 2000-05-01 2003-01-23 Aeropharm Technology Incorporated Core formulation comprising troglitazone and a biguanide
WO2003005991A1 (en) * 2001-07-10 2003-01-23 Aeropharm Technology Incorporated A core formulation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO03005995A1 *

Also Published As

Publication number Publication date
JP2004536843A (en) 2004-12-09
AU2001273289B2 (en) 2004-10-07
WO2003005995A1 (en) 2003-01-23
EP1429747A1 (en) 2004-06-23
MXPA04000180A (en) 2004-11-22
CA2453775A1 (en) 2003-01-23

Similar Documents

Publication Publication Date Title
GB2375299B (en) Playard and a changing table thereof
IL158437A0 (en) Absorbent article having a multilayer absorbent core
EP1455793A4 (en) Antidiabetic formulation and method
HK1136780A1 (en) Multistage formulation containing a biguanide and thiazolidindione derivatives
PL370563A1 (en) Deuterated substituted pyrazolylbenzylsulfonamides and medicaments comprising said compounds
DE60128006D1 (en) Palette aus wellpappe
AU2002337749A1 (en) Pioglitazone hydrochloride
AU2001227535A1 (en) A core formulation
EP1429747A4 (en) Core formulation comprising pioglitazone hydrochloride and a biguanide
TWI315982B (en) Combinations comprising epothilones and pharmaceutical uses thereof
EP1511753A4 (en) Antimicrobial agents and uses thereof
HK1052281B (en) Method and device for manufacturing brush
EP1429732A4 (en) A core formulation
EP1429740A4 (en) Core formulation comprising troglitazone and a biguanide
AU2001273309A1 (en) Core formulation comprising troglitazone and a biguanide
GB0101992D0 (en) Pesticidal formulation
SG104988A1 (en) Leadframe and component with a leadframe
GB0111723D0 (en) A pillow
IL147063A0 (en) Pesticidal formulation
IL161496A0 (en) A combination product comprising melagatran and dexamethasone
AU2001269849A1 (en) A package and methods of manufacturing and using same
GB2372253B (en) A render
GB0102050D0 (en) A puzzle
GB2384987B (en) A head lice formulation
GB0030802D0 (en) Packaging regimen of pseudoephedrine hydrochloride and fexofenadine hydrochloride

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040109

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20041122

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 9/50 B

Ipc: 7A 61K 31/4439 B

Ipc: 7A 61K 31/155 B

Ipc: 7A 61K 9/16 A

17Q First examination report despatched

Effective date: 20050323

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060131